Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma3 cm

Stereotactic ablative radiotherapy (SABR) is a safe treatment approach for hepatocellular carcinoma (HCC) with comparable results to other local therapies. For lesions larger than 3 cm, no definitive standard treatment is present and several options are available. We retrospectively review local control (LC) and survival results of SABR in patients with HCC lesions >3 cm. Between 2012 and 2015, we treated 29 patients (39 lesions) having histological or radiological diagnosis of HCC and at least one lesion sized >3 cm. Patients were prescribed 36–48 Gy in 3–5 fractions (mainly 16 Gy × 3 fractions or 8 Gy × 5 fractions), in 3–5 consecutive days. A total of 15 lesions (52 %) had complete, while 10 (34 %) had partial remission; 3 (11 %) had a stable disease. Mean time for CR achievement was 5.8 months (range 1–17). One- and two-year actuarial LC was 100 %. Moreover, 1- and 2-year progression-free (PFS), cancer-specific and overall survival were 57.9 % [standard error (SE) 0.09; 95 % CI 36.9–74.2] and 41.2 % (SE 0.12; 95 % CI 17.7–63.5), 80.7 % (SE 0.08; 95 % CI 59.6–91.5) and 63.3 % (SE 0.11; 95 % CI 38.4–80.3), 71.7 % (SE 0.08; 95 % CI 51.2–84.7) and 56.2 % (SE 0.10; 95 % CI 33.8–73.6). On multivariate analysis, achieving a CR within the target lesion had a borderline significance with respect to PFS (HR 0.83; SE = 0.014; z −1.15; p = 0.095; 95 % CI 0.71–7.45). Time between HCC diagnosis and SABR delivery ( 12 months) was significantly correlated with OS (HR 16.5; SE 21.5; z = 2.14; p = 0.032; 95 % CI 1.27–213.3) as CLIP score (score: 0–1 vs 2) (HR 5.6; SE 4.6; z = 2.10; p = 0.036; 95 % CI 1.11–27.8). A total of 6 major toxic events (G3–G4) were recorded (20 %). In 2 patients (6 %), a radiation-induced liver disease was seen. In conclusion, SABR provided LC and survival rates comparable to other local therapies for patients with HCC lesion sized >3 cm, with acceptable toxicity profile.